Scandion Oncology Correlations
| SCOL Stock | SEK 0.01 0.0005 4.55% |
The current 90-days correlation between Scandion Oncology and Saniona AB is 0.19 (i.e., Average diversification). The correlation of Scandion Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Scandion Oncology Correlation With Market
Good diversification
The correlation between Scandion Oncology AS and DJI is -0.15 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Scandion Oncology AS and DJI in the same portfolio, assuming nothing else is changed.
Scandion |
The ability to find closely correlated positions to Scandion Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Scandion Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Scandion Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Scandion Oncology AS to buy it.
Moving together with Scandion Stock
| 0.86 | VITR | Vitrolife AB | PairCorr |
| 0.76 | HNSA | Hansa Biopharma AB | PairCorr |
| 0.68 | NANOFS | Nanoform Finland Plc | PairCorr |
| 0.94 | EGTX | Egetis Therapeutics | PairCorr |
| 0.69 | XSPRAY | XSpray Pharma AB | PairCorr |
| 0.89 | TROAX | Troax Group AB | PairCorr |
| 0.79 | EVO | Evolution AB | PairCorr |
| 0.76 | XVIVO | Xvivo Perfusion AB | PairCorr |
Moving against Scandion Stock
| 0.82 | TALK | TalkPool AG | PairCorr |
| 0.79 | HAV-B | Havsfrun Investment | PairCorr |
| 0.55 | CAMX | Camurus AB | PairCorr |
| 0.4 | BIOA-B | BioArctic AB | PairCorr |
Related Correlations Analysis
| -0.37 | 0.47 | 0.4 | 0.29 | EXPRS2 | ||
| -0.37 | 0.04 | 0.02 | -0.11 | HNSA | ||
| 0.47 | 0.04 | -0.08 | -0.19 | FLUO | ||
| 0.4 | 0.02 | -0.08 | 0.31 | SANION | ||
| 0.29 | -0.11 | -0.19 | 0.31 | ONCO | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Scandion Stock performing well and Scandion Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Scandion Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EXPRS2 | 3.39 | (0.29) | 0.00 | (0.50) | 0.00 | 7.38 | 25.59 | |||
| HNSA | 3.17 | (0.24) | 0.00 | (0.29) | 0.00 | 7.24 | 36.81 | |||
| FLUO | 3.35 | (0.01) | 0.00 | (0.07) | 0.00 | 6.38 | 34.51 | |||
| SANION | 4.03 | (0.03) | 0.00 | (0.30) | 0.00 | 9.31 | 26.47 | |||
| ONCO | 3.11 | (0.02) | 0.01 | (0.02) | 3.82 | 7.69 | 27.57 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Scandion Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Scandion Oncology Corporate Management
Elected by the shareholders, the Scandion Oncology's board of directors comprises two types of representatives: Scandion Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scandion. The board's role is to monitor Scandion Oncology's management team and ensure that shareholders' interests are well served. Scandion Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scandion Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annie Rasmussen | Chief Director | Profile | |
| Morten Nissen | G Counsel | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Nils MD | Scientific CoFounder | Profile | |
| Johnny MS | CFO CEO | Profile | |
| Alfredo MD | Chief Officer | Profile |